Skip to main content

Health condition · Clinically reviewed

Dermatofibrosarcoma protuberans, a rare skin sarcoma that hides in plain sight.

Slow-growing, locally aggressive and often mistaken for a scar or cyst - DFSP is highly treatable when diagnosed early and managed in a specialist sarcoma centre.

Jump to treatment
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why trust this guide

  • 01

    Clinically reviewed

    Written by our editorial team and reviewed by a registered UK clinician before publication.

  • 02

    Sourced from guidance

    Checked against NCCN, ESMO and BSSMSD sarcoma standards you can see at the end.

  • 03

    Current for 2026

    Reflects modern UK specialist sarcoma centre pathways, Mohs surgery and imatinib for advanced disease.

Key facts

DFSP at a glance.

The essentials in plain English - what DFSP is, who it affects and how it is treated in the UK today.

  • What it is

    A rare, slow-growing, low-grade cutaneous sarcoma - a locally aggressive soft-tissue tumour of the skin.

  • How common

    Around 4.2 cases per million people per year, with a peak in adults aged 20 to 50. Men and women are affected equally.

  • Genetic driver

    A translocation t(17;22)(q22;q13) fuses COL1A1 with PDGFB, driving PDGFR beta signalling and tumour growth.

  • Where it appears

    Most often on the trunk, shoulders, head and neck or limbs. Genital involvement is rare.

  • Diagnostic delay

    Average five years, because early plaques look like scars, keloids or benign cysts.

  • Mainstay of care

    Complete surgical excision with wide margins or Mohs micrographic surgery in a specialist sarcoma centre.

Why this guide matters

A rare cancer that responds to specialist care.

DFSP is uncommon but well understood. The three ideas below shape everything that follows on this page.

  • Biopsy anything that looks odd

    A slow-growing violaceous plaque that has been called a scar or cyst deserves a biopsy - most DFSP is missed for years.

  • Complete margins matter

    Wide local excision or Mohs micrographic surgery in a sarcoma centre gives the best chance of cure and the lowest recurrence risk.

  • Targeted therapy for advanced disease

    Imatinib, aimed at the COL1A1-PDGFB fusion, can shrink unresectable and metastatic DFSP and change what surgery can achieve.

How the diagnosis is made

From a suspicious plaque to a specialist plan.

The steps a UK dermatology and sarcoma team will normally follow, in order - so you know what to expect and why.

  1. 01

    Assessing

    History and duration

    A slow-growing plaque present for months or years, often mistaken for a scar, keloid or benign cyst.

  2. 02

    Assessing

    Clinical examination

    A violaceous or red-brown plaque, later developing protuberant nodules within it. Rarely painful in the early stage.

  3. 03

    Confirming

    Skin biopsy

    Incisional or excisional biopsy is essential. Histology shows a spindle-cell tumour with a storiform pattern.

  4. 04

    Confirming

    Immunohistochemistry

    CD34 is positive and Factor XIIIa is negative - a key pattern that distinguishes DFSP from benign dermatofibroma.

  5. 05

    Confirming

    Molecular confirmation

    FISH or PCR for the COL1A1-PDGFB fusion is positive in around 90 per cent of cases and guides targeted therapy.

  6. 06

    Planning

    MRI for local extent

    Specialist musculoskeletal MRI maps depth and involvement of fascia or muscle to plan surgery.

  7. 07

    Planning

    Sarcoma MDT review

    All cases are discussed at a specialist supra-regional sarcoma MDT - CT chest is added if fibrosarcomatous change is suspected.

Typical timeline: from biopsy to sarcoma MDT plan in a few weeks at a specialist centre.

Symptoms

What DFSP actually looks like.

A slow-growing violaceous plaque that later develops firm nodules. And the features that mean it is time to see a specialist.

  • Early violaceous plaque

    A flat or slightly raised red-brown or violaceous patch that grows slowly over months to years.

  • Mimics a scar or keloid

    Often mistaken for a scar, keloid, benign cyst or lipoma - a key reason for diagnostic delay.

  • Protuberant nodules

    In the later stage, firm nodules develop within the plaque - the feature that gives DFSP its name.

  • Trunk and shoulders

    The commonest sites are the trunk and shoulders, followed by head and neck and the limbs.

  • Late ulceration or bleeding

    Rarely itchy or painful early on - larger or advanced lesions may ulcerate or bleed.

  • Slow but relentless growth

    Steady enlargement over years is typical - any sudden growth spurt warrants review.

  • Peak in early adulthood

    Most cases present between the ages of 20 and 50, with African American patients more commonly affected.

  • Red flag - fibrosarcomatous change

    Rapid growth, firm nodularity or a change in behaviour can signal fibrosarcomatous transformation.

Treatment

How DFSP is treated in the UK.

Surgery is the mainstay - wide local excision or Mohs micrographic surgery in a specialist sarcoma centre. Targeted therapy with imatinib is reserved for advanced disease.

  • Wide local excision

    Surgical removal with 2 to 3 cm margins in a specialist sarcoma centre remains the standard where Mohs is not feasible.

  • Mohs micrographic surgery

    Preferred where feasible - offers optimal margin control and the lowest recurrence rate. Delivered by a specialist dermatologic surgeon.

  • Reconstruction

    Primary closure, local flaps, skin grafts or tissue expansion by a plastic and oncoplastic team, tailored to the defect and site.

  • Adjuvant radiotherapy

    Considered for positive margins where re-excision is not possible, unusually large tumours or fibrosarcomatous transformation.

  • Imatinib mesylate

    A tyrosine kinase inhibitor of PDGFR and BCR-ABL used for unresectable, locally advanced or metastatic fusion-positive disease.

  • Neoadjuvant imatinib

    Sometimes given before surgery to shrink large tumours and improve resectability - an emerging role in selected cases.

  • Second-line TKIs

    Sunitinib or pazopanib are used selectively under specialist sarcoma oncology supervision when imatinib is not tolerated or effective.

  • Sarcoma chemotherapy

    Doxorubicin-based regimens are reserved for the rare cases with metastatic disease, delivered by a sarcoma medical oncology team.

UK care is delivered through supra-regional sarcoma centres including the Royal Marsden, Bristol, Birmingham, Newcastle, Leeds, Nottingham, Oxford, Cambridge, Manchester and Sheffield.

What this guide is based on

The sources behind every claim on this page.

International and UK specialist sarcoma guidance, current at the time of last review.

Key references

Guidelines and standards we relied on.

A quiet reminder

This guide is for information, not medical advice.

Your dermatologist, sarcoma surgeon and oncologist know your case and can tell you which parts apply to you.

  • NCCN. Clinical Practice Guidelines in Oncology - Dermatofibrosarcoma Protuberans.

  • ESMO. Clinical Practice Guidelines for soft tissue and visceral sarcomas.

  • British Sarcoma Group and BSSMSD. UK guidance for the management of skin and soft-tissue sarcomas.

  • MHRA and NICE. Imatinib mesylate indications and monitoring in advanced DFSP.

Red flags

When DFSP needs urgent specialist review.

Any DFSP suspicion belongs in a specialist sarcoma pathway. These are the situations that need particular urgency.

  • Rapid growth in a stable plaque

    A long-standing plaque that suddenly enlarges may signal fibrosarcomatous transformation and needs urgent sarcoma MDT review.

  • Ulceration or bleeding

    New ulceration, bleeding or fungation of a suspicious lesion warrants urgent dermatology and sarcoma referral.

  • Recurrence after prior excision

    Any nodule at the site of a previously excised DFSP should be biopsied - recurrence risk is lifelong.

  • Firm nodules within an old scar

    New nodularity in what was thought to be a scar or keloid is a classic late presentation of DFSP.

  • Deep fixation to muscle or fascia

    Tethering suggests deep extension - MRI and specialist surgical planning are needed before any excision.

  • Suspected metastasis

    New respiratory symptoms in known FS-DFSP need CT chest - the lungs are the commonest site of the rare metastases.

  • Diagnostic uncertainty on biopsy

    If CD34, Factor XIIIa and morphology do not fit, request FISH or PCR for COL1A1-PDGFB before treatment.

  • Excision at a non-specialist centre

    Local excision without sarcoma MDT input risks positive margins and recurrence - refer to a specialist centre.

  • Psychological distress

    A rare cancer diagnosis carries a real emotional burden - Sarcoma UK, Macmillan and specialist nurses can help.

Living with it

A rare cancer with a good outlook after complete surgery.

Four things that make the biggest difference - long-term follow-up, a specialist centre, good support and reassurance about family risk.

A quiet reminder

Recurrence is preventable when margins are clear.

Historic recurrence rates were up to 20 to 50 per cent with narrow margins. Modern wide excision and Mohs surgery have transformed outcomes.

  1. 01 Follow-up

    Long-term surveillance

    Recurrence risk is lifelong - regular clinical review at a specialist centre matters for years, not months.

  2. 02 Team

    A specialist sarcoma centre

    Care is best delivered at a supra-regional sarcoma centre with sarcoma surgery, Mohs, oncology, dermatology and histopathology in one MDT.

  3. 03 Support

    You are not alone

    Sarcoma UK, Cancer Research UK, Macmillan and a specialist sarcoma nurse can help with information, benefits and emotional support.

  4. 04 Family

    Genetics and reassurance

    DFSP is generally sporadic, not hereditary - genetic counselling can offer reassurance where family concerns arise.

Frequently asked

Everything we get asked about DFSP.

Quick answers on biopsy, surgery, imatinib and long-term follow-up.

  • What is dermatofibrosarcoma protuberans?

    Dermatofibrosarcoma protuberans, or DFSP, is a rare, slow-growing, low-grade cutaneous sarcoma - a soft-tissue cancer of the skin. It is locally aggressive but rarely spreads, with an incidence of around 4.2 cases per million people per year.

  • What causes DFSP?

    Almost all DFSP tumours carry a chromosomal translocation, t(17;22)(q22;q13), that fuses the COL1A1 and PDGFB genes. This drives overexpression of PDGFB and constant activation of the PDGFR beta receptor, which fuels tumour growth. The change is acquired, not inherited.

  • Why is DFSP often diagnosed late?

    DFSP starts as a flat or slightly raised violaceous or red-brown plaque that grows very slowly, often over years. It is easily mistaken for a scar, keloid or benign cyst, and the average delay to diagnosis is around five years.

  • How is DFSP diagnosed?

    Diagnosis relies on a skin biopsy showing the classic spindle-cell pattern, immunohistochemistry that is positive for CD34 and negative for Factor XIIIa, and molecular confirmation of the COL1A1-PDGFB fusion by FISH or PCR. MRI helps map deep extent for surgical planning.

  • What is the best treatment for DFSP?

    Complete surgical removal is the mainstay - either wide local excision with 2 to 3 cm margins or Mohs micrographic surgery, which offers the best margin control and the lowest recurrence rate. Care should be delivered at a specialist sarcoma centre with plastic reconstruction as needed.

  • When is imatinib used?

    Imatinib mesylate is a targeted tyrosine kinase inhibitor used when DFSP is unresectable, locally advanced or metastatic and the COL1A1-PDGFB fusion is confirmed. It can shrink tumours before surgery in selected cases, with response rates reported at around 50 to 80 per cent.

Related content

Keep reading.

Pulse Healthcare concierge

Send us your enquiry

A concierge service for UK private healthcare. We match you with the best vetted clinics and consultants in our network - they then contact you directly.

So we can match you to the right clinician close to you.

We reply to every enquiry within 24 hours (Mon–Fri). Confidential - your details are never shared outside our vetted consultant network.